Fad approves great drug

If approved, neffy would be the first new delivery method in more than 35 years for small children.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Data from the DEVOTE study suggest that 50-milligram doses are safe and effective.

In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.

Insulin efsitora was able to lower A1C in patients with type 1 diabetes but more patients experienced severe hypoglycemic events than patients taking insulin degludec.

Researchers that clinical guidelines highlight the possibility of chronic obstructive pulmonary disease and other conditions masking early symptoms of lung cancer.